PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 16, 20240 citations

Figure S3 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

View Full Paper
SLSun Min LimYonsei UniversityTFToshio FujinoHarvard UniversityCKChulwon KimNational Institutes of Health

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Figure 3. Activity of osimertinib in EGFR 19Del-derived BBT-176-resistant clones. Abbreviation: BR(1/2), BBT-176-resistant (clone 1/2).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lim et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db64358752395fhttps://doi.org/10.1158/1078-0432.27032017.v1
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Figure S10 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
  2. 2Figure S1 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
  3. 3Figure S2 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
  4. 4Figure S6 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024
  5. 5Figure S5 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer2024